Literature DB >> 31726040

Total Absence of Dystrophin Expression Exacerbates Ectopic Myofiber Calcification and Fibrosis and Alters Macrophage Infiltration Patterns.

Christopher N J Young1, Maxime R F Gosselin2, Robin Rumney2, Aleksandra Oksiejuk3, Natalia Chira2, Lukasz Bozycki4, Paweł Matryba5, Kacper Łukasiewicz6, Alex P Kao7, Joseph Dunlop8, Samuel C Robson9, Krzysztof Zabłocki10, Dariusz C Górecki11.   

Abstract

Duchenne muscular dystrophy (DMD) causes severe disability and death of young men because of progressive muscle degeneration aggravated by sterile inflammation. DMD is also associated with cognitive and bone-function impairments. This complex phenotype results from the cumulative loss of a spectrum of dystrophin isoforms expressed from the largest human gene. Although there is evidence for the loss of shorter isoforms having impact in the central nervous system, their role in muscle is unclear. We found that at 8 weeks, the active phase of pathology in dystrophic mice, dystrophin-null mice (mdxβgeo) presented with a mildly exacerbated phenotype but without an earlier onset, increased serum creatine kinase levels, or decreased muscle strength. However, at 12 months, mdxβgeo diaphragm strength was lower, whereas fibrosis increased, compared with mdx. The most striking features of the dystrophin-null phenotype were increased ectopic myofiber calcification and altered macrophage infiltration patterns, particularly the close association of macrophages with calcified fibers. Ectopic calcification had the same temporal pattern of presentation and resolution in mdxβgeo and mdx muscles, despite significant intensity differences across muscle groups. Comparison of the rare dystrophin-null patients against those with mutations affecting full-length dystrophins may provide mechanistic insights for developing more effective treatments for DMD.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31726040     DOI: 10.1016/j.ajpath.2019.09.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  7 in total

Review 1.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

2.  Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts.

Authors:  Maxime R F Gosselin; Virginie Mournetas; Malgorzata Borczyk; Suraj Verma; Annalisa Occhipinti; Justyna Róg; Lukasz Bozycki; Michal Korostynski; Samuel C Robson; Claudio Angione; Christian Pinset; Dariusz C Gorecki
Journal:  Elife       Date:  2022-09-27       Impact factor: 8.713

Review 3.  The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis.

Authors:  Carol M Artlett
Journal:  Biomolecules       Date:  2022-04-26

Review 4.  Macrophages in Skeletal Muscle Dystrophies, An Entangled Partner.

Authors:  Marine Theret; Marielle Saclier; Graziella Messina; Fabio M V Rossi
Journal:  J Neuromuscul Dis       Date:  2022

5.  Selective ablation of Nfix in macrophages attenuates muscular dystrophy by inhibiting fibro-adipogenic progenitor-dependent fibrosis.

Authors:  Marielle Saclier; Giuseppe Angelini; Chiara Bonfanti; Giada Mura; Giulia Temponi; Graziella Messina
Journal:  J Pathol       Date:  2022-04-13       Impact factor: 9.883

6.  P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.

Authors:  Robin M H Rumney; Justyna Róg; Natalia Chira; Alexander P Kao; Rasha Al-Khalidi; Dariusz C Górecki
Journal:  Front Pharmacol       Date:  2022-07-14       Impact factor: 5.988

7.  Specific Dystrophins Selectively Associate with Inhibitory and Excitatory Synapses of the Mouse Cerebellum and their Loss Alters Expression of P2X7 Purinoceptors and Pro-Inflammatory Mediators.

Authors:  Torquil Jackson; Mohsen Seifi; Dariusz C Górecki; Jerome D Swinny
Journal:  Cell Mol Neurobiol       Date:  2021-06-08       Impact factor: 4.231

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.